Andrew J Doorey, MD | |
2610 N Elm St, Lumberton, NC 28358-3011 | |
(910) 671-6177 | |
(910) 671-6770 |
Full Name | Andrew J Doorey |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 46 Years |
Location | 2610 N Elm St, Lumberton, North Carolina |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1568438430 | NPI | - | NPPES |
1568438430 | Medicaid | DE |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Unc Physicians Network | 5496940546 | 709 |
News Archive
MediSapiens, a leading Finnish developer and provider of Bio-IT solutions for research and biomedicine, joins a newly established genomic research project focusing on comparing dog and human genomes to advance human health.
GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (US FDA).
Researchers from Germany and France tried to determine if epidemiological studies based on co-detection prevalence data can offer a reliable estimation of interactions among respiratory viruses. They designed a simulation study by building on a general epidemiological model of co-circulation of 2 respiratory viruses that cause seasonal epidemics.
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
An international study of more than 3.2 million people with severe mental illness reveals a substantially increased risk for developing cardiovascular disease compared to the general population.
› Verified 3 days ago
Entity Name | University Of North Carolina At Chapel Hill |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1780669200 PECOS PAC ID: 0648181156 Enrollment ID: O20031105000359 |
News Archive
MediSapiens, a leading Finnish developer and provider of Bio-IT solutions for research and biomedicine, joins a newly established genomic research project focusing on comparing dog and human genomes to advance human health.
GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (US FDA).
Researchers from Germany and France tried to determine if epidemiological studies based on co-detection prevalence data can offer a reliable estimation of interactions among respiratory viruses. They designed a simulation study by building on a general epidemiological model of co-circulation of 2 respiratory viruses that cause seasonal epidemics.
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
An international study of more than 3.2 million people with severe mental illness reveals a substantially increased risk for developing cardiovascular disease compared to the general population.
› Verified 3 days ago
Entity Name | Unc Physicians Network Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1750704367 PECOS PAC ID: 5496940546 Enrollment ID: O20101115000646 |
News Archive
MediSapiens, a leading Finnish developer and provider of Bio-IT solutions for research and biomedicine, joins a newly established genomic research project focusing on comparing dog and human genomes to advance human health.
GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (US FDA).
Researchers from Germany and France tried to determine if epidemiological studies based on co-detection prevalence data can offer a reliable estimation of interactions among respiratory viruses. They designed a simulation study by building on a general epidemiological model of co-circulation of 2 respiratory viruses that cause seasonal epidemics.
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
An international study of more than 3.2 million people with severe mental illness reveals a substantially increased risk for developing cardiovascular disease compared to the general population.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Andrew J Doorey, MD 2000 Perimeter Park Dr Ste 200, Morrisville, NC 27560-8442 Ph: () - | Andrew J Doorey, MD 2610 N Elm St, Lumberton, NC 28358-3011 Ph: (910) 671-6177 |
News Archive
MediSapiens, a leading Finnish developer and provider of Bio-IT solutions for research and biomedicine, joins a newly established genomic research project focusing on comparing dog and human genomes to advance human health.
GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (US FDA).
Researchers from Germany and France tried to determine if epidemiological studies based on co-detection prevalence data can offer a reliable estimation of interactions among respiratory viruses. They designed a simulation study by building on a general epidemiological model of co-circulation of 2 respiratory viruses that cause seasonal epidemics.
Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.
An international study of more than 3.2 million people with severe mental illness reveals a substantially increased risk for developing cardiovascular disease compared to the general population.
› Verified 3 days ago
Charles R. Beasley, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 395 W 27th St, Lumberton, NC 28358 Phone: 910-739-7551 Fax: 910-738-3764 | |
Dr. Christopher Ronald Walters, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 403 W 27th St, Lumberton, NC 28358 Phone: 910-671-6619 | |
Paul Sierszulski, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 395 W 27th St, Lumberton, NC 28358 Phone: 910-739-7557 Fax: 910-739-2332 | |
Nam Huynh, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 395 W 27th St, Lumberton, NC 28358 Phone: 910-739-7551 Fax: 910-739-2332 | |
Sadanand Belinje Hegde, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 725 Oakridge Blvd Ste A3, Lumberton, NC 28358 Phone: 910-738-1141 Fax: 910-738-6011 | |
Joshua Ruiz, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 West 27th Street, Southeastern Health, Lumberton, NC 28359 Phone: 910-272-1478 Fax: 910-671-5392 | |
Susan Marie Pereira, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 W 27th St, Lumberton, NC 28358 Phone: 910-735-8781 |